I will now hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead. Thank you, Alex. Good morning and good afternoon, everyone. Thank you for joining us on short notice to discuss the U.S. FDA approval of WELTRUZA, olanzapine LAI. The materials are posted to the website this morning, and the press release is also on our website. Before I turn the call over to Richard Francis, I would like to remind everyone that we will be making forward-looking statements on the call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statement due to a variety of factors. These factors are described in our earnings press release and our most recent forms 10-K and 10-Q filed with the SEC. Any statements that we make are only valid as of today, and we undertake no obligation to update those statements subsequently. With that, Richard, the floor is yours. Thank you, Chris. Thank you everybody for joining the call. On the call today will be Eric Hughes, Head of R&D, Chief Medical Officer. For the Q&A, I will be joined by Chris Fox, the EVP, Executive Vice President of U.S. Commercial, and Eli Kalif, Chief Financial Officer. Moving on to the next slide. The next slide, please. Once again, it is great to be having a call with you where we talk about the execution of our Pivot to Grow strategy, a strategy we started back in 2023. A strategy that was designed to move Teva from a pure play, world-class generics company to a world-class biopharmaceutical company. I think we have made incredible progress. If you remember, it was a three-phase strategy. The first was to return to growth. We have done that over the last three years. The second phase was to accelerate growth. That acceleration was going to come to delivering on our growth engines, our innovative products that we have in the market that we often talk about. It was also about really bringing an exciting pipeline to the market. I am really excited today that we are in a position where we can start to talk about that step-up innovation, and see our pipeline start to materialize. If you go on to the next slide, 2026 has already been a year of acceleration, you could say. We have had a number of milestones already this year. The dupilumab maintenance data, the ecopipam accepted by the FDA and given priority review, the anti-IL-15 you saw some data in vitiligo, and recently in Celiac disease. Today is all about WELTRUZA. It is a special day for patients, for physicians, and for families that some of their members have schizophrenia. As Teva, we are really proud to be able to bring WELTRUZA to the market to help this patient population in coping with that condition. So exciting for us at Teva. Exciting that it is a year where we keep bringing new data, new opportunities to drive this long-term acceleration of Teva. With that, I know everybody is excited to hear about the data, so I will hand over to Eric. Thank you, Richard. I really appreciate it. If I could have the first slide. I have to start off by saying we are just delighted by the approval of WELTRUZA by FDA. I just wanted to start off by saying, this begins with the patient. Patients with schizophrenia, it is a devastating disease for patients, and it can be a devastating disease for their families as well. The most important thing is that we do have treatments for schizophrenia. What WELTRUZA will bring, we hope, is that chance of decreasing relapses, because we are going to take advantage of the long-acting injectable for them. This relentless progression, negative, positive cognitive symptoms over years, we want to prevent those relapses, which would cause the hospitalizations and cause the progression of their disease. We have thought about the patient from day one, and we believe that we are really achieving a great thing for them today. Can I have the next slide? This patient population is not insignificant. There are 2.2 million people in the U.S. About 1.5 million of them get treated, and 20% of all those patients who get treated are on oral olanzapine. Olanzapine is a known treatment for schizophrenia. It has powerful efficacy and a known safety profile. Our Teva commercial organization is set up to succeed here. We have a deep understanding of the patient journey, which is very complex. We have been doing and detailing these patients, and caregivers with our UZEDY program, and we are building upon that great expertise. As I mentioned, olanzapine has a demonstrated safety profile, and we have go-to-market capabilities that are, I think, leading in the industry. But let's get to the WELTRUZA on the next slide. WELTRUZA really epitomizes the R&D strategy at Teva. We choose unmet medical needs that need to be addressed. We innovate based on the formulation. We brought and built upon the known safety and efficacy of WELTRUZA. We innovated with the formulation by design to differentiate it for the market. We executed the study with high velocity by accelerating the program six to nine months, and that brought in an on-target submission, which then led to an approval that was right first time. This is our plan. This is how we build upon known science and accelerate it, to bring a treatment for unmet need in patients. We're very proud of this, and I think this is a winning paradigm for our company. Go to the next slide. So what gets us so delighted and elated at Teva this morning? WELTRUZA builds upon the known efficacy and safety of olanzapine. I said this is a tried and true treatment for schizophrenia, and as I mentioned, that's 20% of the oral market right now for patients. But we innovated on it. We brought a once-monthly subcutaneous dose that this has no loading dose, no oral supplementation, and no post-injection monitoring. These are the critical attributes of what we needed to achieve, and we delivered on that completely with this label that we have gotten approved by the FDA. So I'm very proud of the work that the R&D organization has done and the work that we're collaborating with our commercial colleagues to make sure that we get this treatment to patients as quickly as possible. We're very excited by all the results that we've achieved to date. And this really fills a long-standing gap in care. There are no other alternatives for long-acting injectables that are viable, compared to WELTRUZA. So we think that we really are addressing an unmet medical need with the innovations from our labs. Go to the next slide. And I want to bring it back to the patient on this last slide. I said that the most important thing is preventing relapse. That's what long-acting injectables continuously show, that when you get rid of the problem of adherence. Adherence is the problem of breakthrough and relapse with these powerful drugs. By bringing an easily used subcutaneous injection that's once a month, we're chipping away at that adherence problem. And you can see in our follow-on study from SOLARIS in Period 2 out to about one year follow-on, only 4% of the patients relapse. This is a critical element of what we want to help patients do. Get a treatment that's easy to use, well-known, and efficacious, but take away that problem of adherence with a subcutaneous injection once a month. We're very proud of this. We have great hope for patients in the future, and we're looking forward to getting this out as widely as possible. And with that, Richard, I will hand it back to you. Thank you, Eric. Thank you for walking through that. We finish on this slide. I just want to give you a bit of context for this slide. This is the image that you will be seeing around with regard to WELTRUZA. We are doing a DTC campaign with WELTRUZA, and we're doing this because we believe that we have created a real opportunity for these patients, as Eric has mentioned, and the physicians to start treating their patients differently with this molecule. To do that, we want to make sure people are aware of it. Those physicians are aware of it, patients are aware of it, their loved ones are aware of it. So it gives them the chance to get back into that office and have a discussion with their physician. The physicians are also aware of it. So be prepared to see this, and for many of you who know us, this builds on the capability that we built with Austedo, where we had to re-mobilize a patient population with tardive dyskinesia and help physicians start to treat those patients differently for the first time in a long time. So, good capabilities that Eric mentioned we already have in schizophrenia, but good capabilities around how do we mobilize this patient population to help them understand there is a new treatment out there. With that, I will now open it up for Q&A. Thank you. Well, just to give Just a reminder, if you'd like to ask Sorry, Al, go ahead. Sorry. Thank you, Chris. Just as a reminder, if you would like to ask a question, you may press star followed by one on your telephone keypad. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking a question. Our first question for today comes from [Joe Vitone] of TD Securities. Your line is now open. Please go ahead. Hi there. Good morning. Congratulations on approval, and thank you for taking my question. Maybe just as you think about the perfect patient for WELTRUZA versus UZEDY, I guess, do these patients fit in sort of nice targeting boxes for you, or do you think there is going to be overlap? I guess, how do you think about that? Second, our physicians do indicate that they want to use LAIs more in practice, but sometimes there is some logistical hurdles at the site. Obviously, the differentiation and monitoring will be great, but can you talk a little bit more about what Teva is doing to make sure the physicians have a good first experience at the prescribing site for WELTRUZA? Thank you. Thanks, [Joe]. Thank you very much for the call. Very much appreciate it. I know Eric will be itching to answer that one because I think you will hear that we very much thought about the value proposition, what physicians need from LAIs, what they expect that they may not have got, and also what you talk about the co-positioning of these two products. I will hand over to you, Eric. Yeah. Thanks for the question. I heard two things there. Who do we envision starting on WELTRUZA versus UZEDY? The first and most obvious places to start with, those who are on an oral risperidone can take UZEDY, and those who are on an oral olanzapine can start WELTRUZA. I think that's a natural selection that's already out there in the field. What we're delivering, though, to your second point is something that they haven't had before. An injection that is easy to give to a patient. It's subcutaneous. It doesn't require any loading doses. It doesn't require any other supplemental oral medication. A lot of the hurdles of an intramuscular injection— —a complicated way of starting it. We've removed that and given them something that really is a great treatment option for patients with that phenotype, and that will also address the basic problem of relapse due to non-adherence. We've removed a lot of those barriers, and the natural place that I think that the patients will come from is those oral options that they're on already. Remember, 20% of the oral market is olanzapine, and we're providing the first best option that's really viable for a long-acting injectable. Thanks, Eric. Is there anything you'd like to add to that, Chris Fox? Sure. Absolutely. Good morning, everyone. Yeah, this is a really exciting time for us, and I love the nature of your question of how do we instill a more better experience with LAIs. This is something that we've been partnering with Eric and his team on because we know that this was such an untapped need. You can see that even as an example with UZEDY and how we're growing that market because there is starting to be more anticipation of how LAIs specifically prevent relapses as Eric showed in the data and provide a much better experience, not just because there are no loading dose and no oral supplementation, but also it prevents irreversible function decline when these patients have breakthrough symptoms or are non-adherent on an oral. We've been preparing for this launch, I got to say, for a long time. It's been well over a year. We had an extraordinary nationwide launch meeting last week and doing exactly that. Our go-to-market and really the education that we're going to use specifically on olanzapine, but also co-located with UZEDY. I think we're in a unique leadership position to be able to cover most of the schizophrenic patients, about 80% across this continuum of oral olanzapine patients and oral paliperidone and risperidone patients with UZEDY. We're really excited. We've got lots of work to do, but we have the right tools and now importantly, the right franchise in UZEDY and WELTRUZA. Thanks, Chris. Thanks, Eric. Next question. Our next question comes from Umer Raffat of Evercore ISI. Your line is now open. Please go ahead. Hey, guys, this is Mike DiFiore in for Umer. Thanks so much for taking my question and congrats on the approval. Two questions from me. One, are you able to disclose the pricing at this juncture? Number two, just given that I can look back at oral branded olanzapine, Zyprexa, I think it reached around $5 billion in worldwide peak sales. Would you be able to comment whether that potential could be reached with olanzapine LAI? Do you have any at least preliminary comments on what you expect for oral to LAI conversion? Thank you. Thanks, Mike. Thanks for the question. To answer the first question, the wholesale, the WAC price is $2,950, to give you that. Then to the second question, which was touching upon the opportunity here, which is a good question, and I think it's probably based on the product profile that Eric just walked through, as well as the label that we have. Look, we put down in our forecast $1.5 billion - $2 billion for UZEDY and WELTRUZA. I think there's a lot of enthusiasm around WELTRUZA because of the product profile that Eric just talked about. I think for us, it's about making sure we get out there and do what Chris Fox said. Make sure people have an understanding of where these products can be used, how effective they are, how they fit into their clinics, how patients can benefit from the compliance and the adherence. If that plays out well, then obviously we're going to have an ability to hit those targets of $1.5 billion - $2 billion. But I think you probably know, Mike, from talking to us in the past, we tend to think about this in a very thoughtful way. We want to see how this plays out. It is a very managed area, managed care, and so we've got to be thoughtful about that. Let's get started. Let's get the excitement turned into prescriptions. Let's get patients on this drug. Let's get hospital formularies listed in. Let's get Medicaid to have it on their formularies first. Then I think we can talk about what the ambition could be in the long run. But I'm glad you see it as a big step forward for the treatment of schizophrenia patients. So thank you for that. Thank you. Our next question comes from Louise Chen of Scotiabank. Your line is now open. Please go ahead. Hi. Congratulations on the approval and thanks for taking my questions here. I just wanted to ask you on payer coverage, when do you expect that to ramp up and what are the different stages here? What is the out-of-pocket cost per patient? Then the other thing I wanted to ask you about, as we think about modeling the sales, I know the progression will be later on in 2027. But how should we think about growth in that progression and also margins for the product? Thank you. Yeah. Thanks, Louise. I'll probably start the ball a bit and then hand over to Chris Fox on this one. From a payer point of view, as we've spoken about in the past, this is about firstly getting Medicaid on board state by state. As you may well know, these do start at different times. So day one, we get some Medicaid and then some take as much as 12 months, even some beyond that. We think we'll have about 85% coverage at the end of the first year. Medicare is harder, and that's about negotiation. As you've seen with UZEDY, we are all about making sure that we get value and access. We understand that we have a valuable product here because the product profile, and we want to make sure that is appreciated. I think that's how we think about it. That's partly also why, to touch on your point of revenue, we don't see significant revenue in H1 next year because this is about getting all the Medicaid states on board, getting into the hospital formularies, getting some good breadth of use from physicians, and then actually some data. That's what you're seeing in the second half of the year. So that's how we think about it, and that's how you should model it. That's how it comes to the payer access. It's mainly in Medicaid and Medicare. There is a small amount which will be in commercial. Then maybe I'll hand over to Chris to talk a bit more about, one, things about the out-of-pocket, but also the comprehensive services that we have to ensure that patients can get access to this. So over to you, Chris. Thanks, Richard. Great question. We are modeling this similarly, as Richard just said. Our approach is to really balance very wide access with preservation of value. So it's really important to start with those Medicaid patients. As Richard elegantly articulated about the process, it is state by state. So that's something that we'll look to address much like we did UZEDY. The out-of-pocket for patient is very different based on their coverage and if they're dual eligible, all of those things. The team has built a really extraordinary kind of patient hub to be able to help that. So it's a very bespoke service that allows for us to optimize their experience and give them access as early as possible. I think the other big thing I'm excited about is very rarely do we get to launch another product so co-located with a current product, and that's UZEDY. So we have lots of synergies in this space, both in our experience with providing those patient services, prescriber services as well, and as importantly as Eric pointed out, this deep understanding of the patient journey. So, how do they go from oral and get on an LAI? All of those things are such an important part of that. Access is a big part of it, but all of those other surround sound things contribute to that experience as well. So we're excited to apply the learnings and the knowledge that we have and help support patients. Thank you for the question. Thanks, Chris. Thanks for the question, Louise. Next question. Our next question comes from Les Sulewski of Oppenheimer. The line is now open. Please go ahead. Good morning. Thank you for taking my questions and congrats on the approval. I have two, one on distribution and one on the funnel of patients. On the distribution side, given the refrigeration aspect, how are you setting up distribution in buy and bill versus specialty pharmacy, and when do you expect the permanent J-code? Second, on the funnel of patients, you cite the LAI suitable patients at 20% of the oral population. Can you perhaps just walk us through the first year patients come from? Is it best practice switches, recent hospital discharges, or the stable oral patient group? Thank you. Hi, Les. Thanks for joining the call. I'll hand those straight across to Chris Fox. Chris, on the distribution, he has that, and then on the funnel of patients, which will be the first to come across to WELTRUZA. Yeah. Sounds great. Yeah, we assume that based on all the market research that we've done, that an oral olanzapine patient that is not compliant for a variety of reasons would be a perfect olanzapine LAI patient. From what physicians tell us, they're very familiar with the molecule, and they really appreciate the efficacy and the control that it gives them. So in our discussions leading up to this and the market research that we've done, we see that opportunistically as the perfect place to start. We'll see where that goes from there. I mean, some of the experiences that we've had on UZEDY is that once patients come and physicians get experience, they then start to archetype for themselves what that looks like and what the perfect patient profile is. That's something that we'll be interested in keeping you guys updated on. But we certainly think that that's going to be where we start and where we go from there. I think that this is going to be a very broad opportunity, as Eric said, given that oral olanzapine represents about 20% of the total patients. On the distribution question, just general code, so we don't have to wait for a J-code. We expect to launch as we did with UZEDY. So we will have products available, sample and hospital kits as well, so physicians can have those experiences and then get the product in channel in the next couple of weeks, and get patients on therapy. Thanks for the question. Thanks, Chris. Thanks for the question, Les. Next question. Our next question comes from David Amsellem of Piper Sandler. Your line is now open. Please go ahead. Hey, thanks. If you take a step back and look at the LAI antipsychotic space, I think the share of all LAIs is somewhere in the teens. I guess my question here is, as you think about this product, can you give us a sense of where you think its share of the market could be in terms of percentage of oral olanzapine switches? Do you think that share could ultimately be higher in terms of percent of LAI to oral? That's number one. Then as you think about market expansion down the road, any comments on bipolar mania? I know oral olanzapine also is used quite significantly in mania, so any thoughts on that program? Thanks. Thanks, David. Thanks for the question. A lot of people ask us this question. When we think about, you said, the teens, it actually varies a bit. It's around about 13%-14%, the LAI market. Slightly higher in Europe, by the way, worth noting. That is obviously a non-olanzapine, because as Eric pointed out, there is not a used long-acting olanzapine on the market right now. So an analog could be, well, the same will happen in olanzapine. So 13% transfer to LAI. That's a very crude way of looking at it, but obviously that is something that's already happened, and that's fairly significant. Would that change with olanzapine LAI? Would it be the same? Would it be lower? Would it be higher? We'll wait and see. What we do know, and what I think Chris Fox highlighted is, through the market research we see, there is significant demand for this, and I think Eric mentioned it in his opening remarks. Compliance is key when you have severe schizophrenia. They have been anticipating having an effective monthly treatment for some time, combined with the fact that obviously this has loading, it hits therapeutic levels very quickly, et cetera. So I think that makes us feel optimistic. But if you're sort of trying to model it, then I would say, yeah, 13% is a good analog. Let's see how it plays out. In Europe, it's slightly higher. But this creates still a very significant opportunity for us. On the bipolar mania, I'll hand that to Eric, and maybe he can give some context of that. Yeah. Thank you, Richard. Thank you, David, for the question. We have been thinking about bipolar and other things that we can do in lifecycle management. I think that with this launch, we'll continue to double down on what we can do in the future, but that's certainly one of the things we've been thinking about. As you know, we got the same indication for UZEDY before, and that was on a monthly simulation basis. I think we'll probably be running a study if we do it for olanzapine LAI, but certainly a good opportunity. Thanks, Eric. Thanks for the question, David. Next question. Our next question comes from Jason Gerberry of Bank of America. Your line's now open. Please go ahead. Hey, good morning, guys. Thanks for taking my questions. For me, I'm just curious how the sales force is going to be prioritizing the two LAIs now, and will UZEDY still get a lot of attention now that there's this new shiny toy in the portfolio? So that's question one. My second question is just, what are you guys assuming for drop-off to patients who go on to olanzapine LAI due to the elevated metabolic risks, which are just a risk associated with this API. How do you think about the drug and stay time? I don't know if there's learnings you can take from oral therapy olanzapine versus other atypicals as weight and other metabolic parameters go in the wrong direction. I just wonder, is there a higher discontinuation rate for patients who start olanzapine versus other atypicals? Thanks. Hi, Jason. Thanks for the questions. I'll hand those to Chris and Eric. Starting Chris on the sales force prioritization. How do they The shiny toy. What happens there? I love it. It is a shiny toy for sure. So is UZEDY, I got to say. We love both of these products, and I think they serve different needs. But in total, as I said before, I think we can cover about 80% of the schizophrenia patients offering them an LAI that they otherwise wouldn't have had that option. We have been meeting with the sales force. They're super prepared. They can do both of these really, really well. 80% of the docs that we call on today already will be targets for WELTRUZA. It's a really, really nice synergy. As you probably can tell, I'm very excited about it, but our reps in management are, too. They really have honed their craft and are doing an extraordinary job of understanding the patient flow and the office flow. They know all of these physicians, and I think that creates a really beautiful slipstream for us to step in and offer them a new alternative, all the while validating the patients that are appropriate for UZEDY and supporting them with both of these tremendous assets. So we think we have a great advantage of having a lot of synergies in this space from a know-how and also from a physician certainty. Eric, I'll turn it over to you. Yeah. The question was about the AE profile of oral olanzapine and the rate at which people drop off or manage that. Well, although that sounds like a bad thing, the great thing about WELTRUZA is we're building upon a known foundation of olanzapine. Physicians know how to use it. They know what to expect. They know how to monitor their patients. Our side effect profile is identical to the oral. So we're adding an innovation and a benefit on top of what they already know. That isn't going to be the biggest barrier. What the positive is that we're bringing them something that actually makes it more convenient to give the drug in a more efficient way so that we remove the problem of adherence. So, I'm particularly excited about that 4% relapse risk. 96% of the people who are stable are staying on the drug because it's working. That's how I think most physicians will approach it. Thank you, Eric. Thanks for the question, Jason. Next question. Our next question comes from Ash Verma of UBS. Your line is now open. Please go ahead. Thanks. Morning. This is Dee on behalf of Ash, and just congrats on the news. I have a couple on the launch trajectory. Can you give us some, I guess, product analog that we can look for the launch trajectory? Then the second thing is, you mentioned the oral conversion to LAI could be 13%. I just wonder, do you have a patient split between conversion from oral versus from other LAI agents? Then my last question is just on the gating factor. What are some of the gating factors for the launch, given that, I guess, the meaningful contribution won't come in till second half next year? Thank you. Yeah. Thanks for the question. I think when it comes to the launch trajectory, I think the way to think about it is, it's about getting a few things in place. First, it's about getting the coverage, and so that's Medicaid. Making sure you get the Medicaid states on board. As I mentioned earlier, that's a site rate limiting step because some will do it in day one, and some will do it in six months, and some in 12, and some even in 18. That's just the procedure they have. You need Medicaid for physicians to start to use it in any volume. We're good at doing that. We know how to do that. We did that with UZEDY. The other one is to get hospital formularies, because obviously many of these patients will end up in the hospital. Once again, we've done that with UZEDY. We know who the people are in the hospital formulary committees, so we know where we need to go. The other is the physicians. As Chris eloquently pointed out, UZEDY salesforce commercial teams call on 80% of these physicians all the time. I think that gives us a good opportunity for a good trajectory. The trajectory should be thought about use of our samples, scripts, hospital formularies, how many physicians use it, what's the breadth of physicians, and then what is the depth of physicians. That's the reason why we talk about more trajectory in those ways versus revenue is because, as I've highlighted, that rate limiting step of payer access, which means that it's really the second half of next year that we'll see meaningful revenue come through. But you'll see all those leading indicators of volume of script, TRX, and the use of the sampling, the factors which we'll be able to articulate why we believe this will be a very good launch. But obviously that's something which we will be mentioning on our quarterly earnings calls. Second, where do these come from? Is it oral? Is it LAIs? I think predominantly, it'll come from orals because people on oral olanzapine will want to. Compliance is key for them or in their physician's eyes or the patient's eyes, will want to move across to WELTRUZA. So what we've seen on all others is that the patients who are on the molecule already, because the physician has chosen olanzapine for a reason, and I think Eric has highlighted it, most of the time they'll pick it because of its efficacy. So we see the majority of patients coming from oral olanzapine onto the LAI. Will some come from other LAIs? That's possible, because maybe they were put on that because of compliance reasons. But think of it in that way. Then I think you said gating factors. I think probably going back to the gating factors are coverage, Medicaid, and hospital formularies. But those we've planned out and I hope you felt from Chris Fox's answer. The thoroughness of the preparation of this launch is excellent. But the thoroughness of this preparation through a team who are already in this market, I think, just makes it even more impactful. So I hope those answer your questions. I don't think I missed anything. Apologies if I did, but next question. Our next question comes from Umer Raffat of Evercore ISI. Your line is now open. Please go ahead. Hi, guys. Thanks for taking my question and congrats on the approval. I have three quick ones if I may. Perhaps first, for Eric. Eric, is there a post-marketing requirement? If you could also speak to the underlying tech, because the label does get into the PDSS cases, but it constantly keeps saying it was on another extended-release olanzapine. Could you just speak to your technology and the Medincell platform as well? Then for you, Chris, and perhaps Richard as well. I noticed the pricing philosophy Teva used on UZEDY was, A, it was not flat pricing, and B, the range across doses was anywhere from $2,000 to $7,000. On this one, it is flat pricing, first of all, but also the price is kind of like in between at $3,750. I understand Velsar is not a comp because that pricing is from 2010, but how should we think about that and why is it flat pricing? I mean, because UZEDY, you can ramp up to almost to $7,000. I am just trying to think out loud about this price point. Okay, Umer. Thanks for the question. I will start with Eric. We can talk about the post-marketing question, and the Medincell technology, which I think he will love to talk about. Then I will hand over to Chris Fox, who can talk about the pricing that you have mentioned, Umer. Yeah. Thank you, Umer. Thanks for the question. With regards to the post-marketing commitment, there is no particular post-marketing commitment other than monitoring for any suspected PDSS in the future, which is something we would be doing anyways through a pharmacovigilance. That is probably the only thing we will be doing in the background, doing expedited events reporting if that is coming up. But nothing particularly unusual about that. The second thing about the technology, I think that in our discussions with FDA, they saw the value of what we were bringing to the table with this technology. Remember, it is a subcutaneous injection that rapidly aggregates under the skin. It was specifically designed to make sure that the safety profile was good. In fact, some of that data, if you look deep into the label, is mentioned there. There is a mention of the fact that this other product, this injectable version of olanzapine, has a dissolution rate in 24 hours of 91%, while I believe the number for WELTRUZA is 7% over 12 hours in an in-vitro assay. That was actually fantastic data to have in the label to really point out what the value of this formulation is that theoretically brings to the patient. So, no significant post-marketing commitments and the technology is highlighted in the label compared to another product out in the market. With that, I will pass it over to Chris. Thanks. Thanks, Umer, for the question. Very astute observations, and I would say that we really thought about this differently than UZEDY, and mainly because UZEDY can come in one or two months. So when thinking about WELTRUZA, we still used the same principle of striking that right balance by having as broad of access as we can, while value preservation. We did not want to unknowingly disincent someone from using the dose that they need because of pricing, and so this was the best way to go. We do, as you can appreciate, massive market research on this to try to get this right, and we feel like this reflects the innovation and also will ensure that we get the best adoption and access across the board. Thank you for the question. Thanks, sorry. Thanks, Chris. Thanks, Umer. Thanks for the question. At this time, we currently have no further questions, so I'll hand it back to Richard Francis for any further remarks. Thank you. Thank you everybody for joining the call. I do appreciate you giving us your time. Just like to reiterate, we are very excited here at Teva as we continue to execute on our Pivot to Growth strategy, particularly on our drive to create a world-class biopharma company by launching innovative products on a regular basis. As you saw, we have five submissions in five years, so we really have some momentum here. What Chris and her team have done in commercializing these products, I think should give people a lot of optimism as to what we can do with WELTRUZA. Just to remind, and many of the questions today have been around this huge unmet medical need there is in schizophrenia, particularly for a long-acting olanzapine molecule, and particularly one with the product characteristics that Eric has clearly highlighted. For me, somebody who's been in this industry a long time, I know I speak on behalf of my colleagues. It's a real privilege to bring something to the market that allows patients suffering from this very difficult condition to have an improved quality of life, that they so desperately want, and for physicians to help them treat those patients. Very proud and I look forward to giving you an update of how we do with the launch at our various quarterly earnings. For me, very excited. Thank you for your time, and wish you all a good weekend. This concludes today's conference call. Thank you all for joining. You may now disconnect your lines.